Search

Displaying results 2801 - 2810 of 8009 in total
  1. Drug

    Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10799
    ApprovedInvestigational

    Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria … The vaccine contains *N. meningitis* serogroup c capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from Corynebacterium diphtheriae

  2. Drug

    Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10800
    ApprovedInvestigational

    Neisseria meningitidis group y capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria … The vaccine contains* N. meningitis* serogroup y capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from Corynebacterium diphtheriae

  3. Drug

    Methylphenidate

    go.drugbank.com/drugs/DB00422
    ApprovedInvestigational

    for children, adolescents, and adults as recommended by CADDRA (Canadian ADHD Resource Alliance). … [L6037] CADDRA recommends the use of methylphenidate due to long term studies, of over twenty years in duration, which show methylphenidate is safe and effective.

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  4. Drug

    Isosorbide

    go.drugbank.com/drugs/DB09401
    ApprovedInvestigational

    Isosorbide was previously available in an oral formulation for the reduction of intraocular pressure. It was approved by the FDA in 1980, but has since been discontinued. … Refer to these drug entries for more information.

  5. Drug

    Abiraterone

    go.drugbank.com/drugs/DB05812
    ApprovedInvestigational

    [A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April,[A260880] July,[L47745] and September 2011,[A260880] respectively. … [L54773,L54768] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability

  6. Drug

    Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen

    go.drugbank.com/drugs/DB10798
    ApprovedInvestigational

    Neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria … The vaccine contains *N. meningitis* serogroup a capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from Corynebacterium diphtheriae

  7. Drug

    Diroximel fumarate

    go.drugbank.com/drugs/DB14783
    ApprovedInvestigational

    More than 80% of patients suffering from this disease have relapsing-remitting MS. … [A187535] Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS.

  8. Drug

    Trolamine

    go.drugbank.com/drugs/DB13747
    ApprovedInvestigational

    Trolamine, which is also referred to as triethanolamine (TEA), is a tertiary amine and a triol. It is a bifunctional compound that exhibits both properties of alcohols and amines. Trolamine contains small amounts of diethanolamine and et...

    Categories: Preparations for Treatment of Wounds and Ulcers
  9. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    [L45300] On April 24, 2024, sparsentan was granted conditional marketing authorization by the European Commission for the treatment of adults with primary IgAN.[L51559] … >A</sub>R and 0.8 nM for AT<sub>1</sub>R).

  10. Drug

    Iptacopan

    go.drugbank.com/drugs/DB16200
    ApprovedInvestigational

    [A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH. … Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor

    Categories: Compounds used in a research, industrial, or household setting